Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

  • STATUS
    Recruiting
  • End date
    Oct 31, 2024
  • participants needed
    150
  • sponsor
    AstraZeneca
Updated on 11 November 2021

Summary

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Description

Patients be randomized in a 1:1 ratio into 2 arms to receive either acalabrutinib monotherapy (Arm A) or rituximab in combination with chlorambucil (Arm B). The primary objective of this study is to compare the efficacy of acalabrutinib relative to chlorambucil plus rituximab in subjects with previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation.

Details
Condition Untreated Chronic Lymphocytic Leukemia
Treatment Rituximab, Chlorambucil, acalabrutinib
Clinical Study IdentifierNCT04075292
SponsorAstraZeneca
Last Modified on11 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Men and women: (a) 65 years of age OR (b) >18 and <65 years of age, provided that they meet at least one of the following criteria: (i) Creatinine clearance 30 to 69 mL/min using the Cockcroft-Gault equation (iwCLL guidelines) (ii) A score higher than 6 on the Cumulative Illness Rating Score-Geriatric (CIRS G)
ECOG performance status of 0, 1, or 2
Diagnosis of CLL that meets published diagnostic criteria (Hallek 2018)
Active disease per IWCLL 2018 criteria that requires treatment
Adequate bone marrow function
Adequate renal and hepatic function

Exclusion Criteria

Known detected del(17p) or TP53 mutation
Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (eg, Richter's transformation, PLL, or diffuse large B cell lymphoma [DLBCL]), or central nervous system (CNS) involvement by leukemia
History of prior malignancy except for the following: (a) Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study (b) Other cancers not specified above which have been curatively treated by surgery and/or radiation therapy from which subject is disease-free for 3 years without further treatment
Significant cardiovascular disease
Known history of infection with human immunodeficiency virus (HIV)
Serologic status reflecting active hepatitis B or C infection
Any active systemic infection (eg, bacterial, viral, or fungal infection) requiring systemic treatment
History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
Major surgical procedure within 30 days of first dose of study drug
Any prior CLL-specific therapies
Corticosteroid use >20 mg within 1 week before first dose of study drug, except as indicated for other medical conditions
Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
For women only: breastfeeding or pregnant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note